

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Serial No.:	07/ 978,891	Group Art Unit:	1644
Confirmation No.:	4493	Examiner:	R.B. Schwadron
Filed:	13 November 1992		
Applicant:	Darrell R. ANDERSON et al.		
For:	Therapeutic Application of Chimeric and Radiolabeled Antibodies to Human B Lymphocyte Restricted Differentiation Antigen for Treatment of B Cell Lymphoma		

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

POWER OF ATTORNEY BY ASSIGNEE AND CHANGE OF CORRESPONDENCE ADDRESS

The assignee of the entire right, title, and interest in U.S. patent application serial no. 07/978,891, Biogen Idec Inc., hereby revokes all previous powers of attorney in the above-identified patent and appoints the practitioners associated with

CUSTOMER NUMBER 47553

as its attorneys and agents to prosecute the captioned application and to transact all business in the U.S. Patent and Trademark Office connected therewith.



Direct all correspondence regarding this patent, except as noted below, to the address associated with **CUSTOMER NUMBER 47553**.

Please note the **new attorney docket number** for this application, **27693-01001**.

Pursuant to 37 C.F.R. § 3.73(b), the undersigned states that Biogen Idec Inc. is the assignee of the entire right, title, and interest in the captioned application by virtue of an assignment from the inventors to IDEC Pharmaceuticals Corp. as recorded in the Patent and Trademark Office at Reel 6440/ Frame 0922. Biogen Idec Inc. is the successor in interest to IDEC Pharmaceuticals Corp.

The undersigned, whose title is supplied below, is authorized to act on behalf of the assignee.

Respectfully submitted,


Date

Christopher A. Dayton
Associate General Counsel, IP
Biogen Idec Inc.